A Phase I Study of NP-G2-044 in Patients with Advanced or Metastatic Solid Tumors (including Lymphoma)


Full Title

NP-G2-044-P1-01: First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients with Advanced or Metastatic Solid Tumors (including Lymphoma)


The purpose of this study is to find the highest dose of the investigational drug NP-G2-044 that can be given safely in patients with advanced or metastatic solid tumors, including lymphoma. Laboratory studies have shown that NP-G2-044 appears to block the ability of cancer cells to travel and spread throughout the body by interfering with the function of a protein called fascin. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced or metastatic breast, pancreas, prostate, lung, colon, esophagus, liver, or ovarian cancer or lymphoma that persists despite treatment.
  • At least 2 weeks must pass between the completion of prior therapies and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Ann Sisk at 646-888-4226.